Compare compounds

MOTS-c

Start

5 mg

Range

5–10 mg per week

Frequency

1–2× weekly

Cycle

6–8 weeks

Vials

10 / 40 mg

5-Amino-1MQ

Vials

10 / 50 mg

Dosing data

Lab reference — not listed

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. In mice it acts mainly on skeletal muscle, inhibiting the folate cycle and purine synthesis, which activates AMPK; under metabolic stress it moves to the nucleus and regulates gene expression.

5-Amino-1MQ

5-Amino-1MQ is a small-molecule (not peptide) inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism. In cultured adipocytes, NNMT inhibition was studied for effects on 1-methylnicotinamide and intracellular NAD+; these observations do not establish a human metabolic response.

MOTS-c

• In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity.
• Plasma levels of MOTS-c decline with age, according to a 2023 review.

5-Amino-1MQ

• Methylquinolinium NNMT inhibitors were selective and membrane-permeable, and reversed high-fat-diet-induced obesity measures in mice.
• In diet-induced obese mice, NNMT inhibition combined with a low-fat diet normalised adiposity and weight to lean-control levels and produced a distinct gut microbiome.

MOTS-c

• Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
• A 2023 review notes no effective clinical method of using MOTS-c has been developed; evidence is preclinical.

5-Amino-1MQ

• Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
• Evidence is limited to cell and mouse studies; no human trials are cited.

MOTS-c

2 references · view

5-Amino-1MQ

2 references · view